Sort by
Keyphrases
Anticancer Activity
14%
Antiproliferative Activity
28%
C-terminal Inhibitors
100%
Cancer Cells
28%
Client Proteins
14%
Clinical Trials
14%
Co-immunoprecipitation (co-IP)
14%
Cytotoxicity
14%
Direct Binding
14%
Diversity Arrays Technology (DArT)
14%
Drug Discovery
14%
Heat Shock Protein 90 (Hsp90)
100%
Heat Shock Protein 90 Inhibitor
42%
Heat Shock Response
57%
Hormone-sensitive Prostate Cancer
100%
In Cancer
28%
In Vivo Efficacy
14%
Inhibition Assay
14%
LNCaP
14%
Luciferase
14%
Molecular Chaperone
14%
Proof of Concept Study
14%
Prostate Cancer
42%
Prostate Cancer Cells
100%
Protein Degradation
14%
Rat Tumor
14%
Size Exclusion Chromatography
14%
Surface Plasmon Resonance
14%
Terminal Heat
28%
Therapeutic Agents
14%
Tumor Model
14%
Western Blot
14%
Xenograft Studies
14%
Biochemistry, Genetics and Molecular Biology
Antineoplastic Activity
14%
Antiproliferative Activity
14%
C-Terminus
100%
Cancer Cell
100%
Clinical Trial
14%
Cytotoxicity
28%
Efficacy Study
14%
Heat Shock Protein
100%
Heat Shock Protein 90 Inhibitor
42%
Heat Shock Response
57%
Immunoprecipitation
14%
LNCaP
14%
Luciferase
14%
N-Terminus
14%
Protein Catabolism
14%
Size-Exclusion Chromatography
14%
Surface Plasmon Resonance
14%
Western Blotting
14%
Pharmacology, Toxicology and Pharmaceutical Science
Androgen
100%
Antiproliferative Activity
14%
Chaperone
14%
Clinical Trial
14%
Cytotoxicity
28%
Drug Discovery
14%
Efficacy Study
14%
Heat Shock Protein 90
100%
Heat Shock Protein 90 Inhibitor
42%
Immunoprecipitation
14%
Luciferase
14%
Malignant Neoplasm
57%
Prostate Cancer
100%
Surface Plasmon Resonance
14%
Tumor Model
14%
Western Blot
14%